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Background: Hyperekplexia is caused by defective glycinergic neurotransmission.
Results:A dominant negative glycine transporter-2 mutant is trapped in a calnexin-bound state and retains wild type GlyT2 in
the endoplasmic reticulum.
Conclusion: Chemical chaperones rescue the folding defect of the mutant and overcome its dominant negative effect.
Significance:This opens the way to revert the dominant negative effect exerted by themutant associated with hyperekplexia in
neurons.
Hyperekplexia or startle disease is a rare clinical syndrome
characterized by an exaggerated startle in response to trivial
tactile or acoustic stimuli. This neurological disorder can have
serious consequences in neonates, provoking brain damage
and/or sudden death due to apnea episodes and cardiorespira-
tory failure. Hyperekplexia is caused by defective inhibitory gly-
cinergic neurotransmission. Mutations in the human SLC6A5
gene encoding the neuronal GlyT2 glycine transporter are
responsible for the presynaptic formof the disease. GlyT2medi-
ates synaptic glycine recycling, which constitutes the main
source of releasable transmitter at glycinergic synapses.
Although the majority of GlyT2 mutations detected so far are
recessive, a dominant negative mutant that affects GlyT2 traf-
ficking does exist. In this study, we explore the properties and
structural alterations of the S512R mutation in GlyT2. We ana-
lyze its dominant negative effect that retains wild-type GlyT2 in
the endoplasmic reticulum (ER), preventing surface expression.
We show that the presence of an arginine rather than serine 512
provoked transporter misfolding, enhanced association to the
ER-chaperone calnexin, altered association with the coat-pro-
tein complex II component Sec24D, and thereby impeded ER
exit. The S512Rmutant formed oligomers withwild-typeGlyT2
causing its retention in the ER. Overexpression of calnexin
rescued wild-type GlyT2 from the dominant negative effect
of the mutant, increasing the amount of transporter that
reached the plasma membrane and dampening the interaction
between the wild-type and mutant GlyT2. The ability of chemi-
cal chaperones to overcome the dominant negative effect of the
disease mutation on the wild-type transporter was demon-
strated in heterologous cells and primary neurons.
The extracellular concentration of synaptic glycine is regu-
lated by Na-and Cl-dependent glycine reuptake (1). The
neuronal GlyT2 transporter is involved in the removal and
recycling of glycine from inhibitory synapses, generating a flux
from the synaptic cleft to the presynaptic terminal and supply-
ing substrate to the low affinity vesicular inhibitory amino acid
transporter (2, 3). Therefore, the synaptic glycine taken up by
GlyT2 is themain source of the releasable transmitter at glycin-
ergic synapses (4, 5). Accordingly, inactivation of the mouse
GlyT2 gene generates a complex postnatal neuromotor pheno-
type that mimics clinical signs of human hyperekplexia (2).
Hyperekplexia or startle disease (OMIM 149400) is a rare
neurological disorder characterized byneonatal hypertonia and
exaggerated startle responses to trivial but unexpected tactile
or acoustic stimuli (6). The most severe consequences of the
disease include brain damage and even sudden death from
lapses in cardiorespiratory function. Although the majority of
patients survive, they may suffer unprotected falls throughout
their entire life that could result in injury (7). Startle disease is a
glycinergic synaptopathy that disrupts postsynaptic or presyn-
aptic inhibitory glycinergic neurotransmission. Themain genes
implicated in startle disease are those corresponding to the gly-
cine receptor and related postsynaptic proteins (8, 9), with
genetic analyses revealing mutations in the human GlyT2 gene
(SLC6A5; solute carrier 6A5) to be the most common cause of
presynaptic hyperekplexia (10–12) and a very common cause
of the disease. Themajority ofGlyT2mutations found in hyper-
ekplexia patients are recessive and cause biallelic loss of func-
tion due to the absence of the protein from the plasma mem-
brane or to the generation of inactive transporters. Recently, a
dominantly inherited mutation affecting the function that also
reduces the expression of the transporter at the cell membrane
was identified and characterized (13). In addition, one interest-
ing mutation is S512R, the sole dominant negative disease-as-
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sociated mutation affecting transporter trafficking. This
mutant transporter prevents the wild-type protein from reach-
ing the plasma membrane, although its exact mechanism of
action has yet to be fully defined (10).
GlyT2 belongs to the SLC6 solute carrier family of neu-
rotransmitter sodium symporters. This family groups together
12-transmembrane domain transport proteins including the
GABA (-aminobutyric acid) andmonoamine transporters (14,
15). A model of the three-dimensional structure of GlyT2 was
recently generated (16) based on the leucine transporter from
Aquifex aeolicus (LeuTAa), a prokaryotic SLC6 homologue (18).
This model provided important clues to explain the effects of
selected missense mutations on critical residues involved in
Na and glycine binding (8, 10–13). More recently, the crystal
structure of a eukaryotic SLC6, the dopamine transporter
(DAT)3 from Drosophila, was resolved (19). Among the differ-
ences from the prokaryoticmodel, the presence of a cholesterol
binding site is particularly relevant in the context of DAT and
GlyT2, which are lipid-raft-associated transporters (20).
During GlyT2 synthesis, the nascent polypeptide is co-trans-
lationally translocated to the membrane of the endoplasmic
reticulum (ER) (21). Correct folding of the transporter is stabi-
lized by its fourN-glycan chains, but it also requires an interac-
tion with several ER chaperones (22). For example, calnexin
(CNX) transiently binds to an intermediate hypoglycosylated
transporter precursor, and it facilitates GlyT2 processing. The
binding of GlyT2 to CNX is mediated by glycan- and polypep-
tide-based interactions, allowing CNX to discriminate between
different GlyT2 conformational states through a lectin-inde-
pendent chaperone activity (23, 24). In addition, oligomer
assembly is a prerequisite to export the SLC6 transporters from
the ER and for their subsequent delivery to the plasma mem-
brane (25). Accordingly, a model has been proposed in which
transporter intermediates are engaged by ER chaperones, and
they are delivered to the coatomer protein II (COPII) prior to
forming oligomers that can subsequently be exported out of the
ER (25, 26). In the present study, we characterize the features
and behavior of the dominant negative hyperekplexiamutant in
the early secretory pathway. We confirmed its dominant nega-
tive effect on the trafficking of wild-type GlyT2 by means of an
interaction in common oligomers. We found that this mutant
transporter provoked the retention of the wild-type GlyT2 in
the ER, an effect that could be reverted by the overexpression of
CNX. An excess of this chaperone increased the amount of
wild-type transporter that reaches the plasma membrane by
preventing the interaction between wild-type and mutant
GlyT2. The effect of pharmacological chaperones in the rescue
of GlyT2 was analyzed in heterologous cells and transfected
cortical neurons.
EXPERIMENTAL PROCEDURES
Cell Growth and Protein Expression—COS7 cells (American
Type Culture Collection) were grown at 37 °C and 5% CO2 in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum. Transient expression was
achieved using NeofectinTM (MidAtlantic Biolabs), according
to the manufacturer’s protocol (24), and the cells were then
incubated for 48 h at 37 °C. Reproducible results were obtained
with 50–60% confluent cells on 60-mmor 6-well plates, using 5
and 2 g of total DNA, respectively. In co-transfection experi-
ments, 25% of the total DNAwas wild-typeDNA. The transfec-
tion efficiency was determined by co-transfecting the cDNAs
with the pSV--galactosidase plasmid (Promega) and meas-
uring -galactosidase activity 24 h later, as described elsewhere
(24).
Plasmid Constructs—The pRFP vector (27) was a generous
gift of José Antonio Esteban (Centro de Biología Molecular
Severo Ochoa, Madrid, Spain). The Myc-Sec24D and HA-
GlyT2 constructs in the pcDNA3 plasmid (Invitrogen) were
generously provided by Francisco Zafra (Centro de Biología
Molecular Severo Ochoa). GlyT2 (28) was subcloned into
pcDNA3 or pRFP (BglII-SalI sites), and the GlyT2 mutants
were constructed by site-directed mutagenesis using the
QuikChange kit (Stratagene) (29). S512R was subcloned in the
unique EcoRI andXbaI sites flankingHA-GlyT2. The complete
coding region of all of the constructs was sequenced to verify
that only the desired mutation had been introduced. Plasmids
from two independent Escherichia coli colonies were trans-
fected into eukaryotic cells, and [3H]glycine transport was
measured in the cells for verification. The GFP-GlyT2 plasmid
was constructed and characterized as described previously (30,
31). TheRFP andHA tagswere fused in framewithGlyT2 at the
N terminus, and they did not interfere either with the uptake
capacity in [3H]glycine uptake assays or its expression at the
plasma membrane as assessed by biotinylation (see Fig. 5A).
C-terminal tagging was avoided because previous reports indi-
cated that this region of the transporter might be involved in
specific interactions and intracellular trafficking (32). TheCNX
cDNA clone (IMAGE number 2582119) in pCMV.SPORT6
was purchased from Source Bioscience Lifesciences (24).
Transport Assays—Glycine transport assays on COS7 cells
were performed at 37 °C in phosphate-buffered saline (PBS)
containing 10 mM glucose and 2 Ci/ml 2-3H-labeled glycine
(1.6 TBq/mmol; PerkinElmer Life Sciences), diluted to a final
concentration of 10 M, as described previously (24). For glu-
tamate transport assays, the radiolabeled glycine was substi-
tuted with the same amount of 3H-labeled glutamate. These
reactions were run for 10 min and then terminated by aspira-
tion. The protein concentration was determined in aliquots
taken from each well (Bradford), and the uptake of [2-3H]gly-
cine was measured by liquid scintillation (LKB 1219 Rackbeta).
Transport was quantified by subtracting the glycine accumu-
lated in mock-transfected COS7 cells (or in the presence of the
specific GlyT2 inhibitor, ALX1393) from that of the transport-
er-transfected cells and normalized to the protein concentra-
tion. Assays were performed in triplicate or quadruplicate.
Surface Biotinylation—COS7 cells expressing wild type or
mutant GlyT2were grown in 6-well plates (Nunc), washed, and
labeled with Sulfo-NHS-Biotin (1.0 mg/ml in PBS; Pierce) at
4 °C, a temperature that blocks membrane trafficking of pro-
teins. After quenching with 100 mM L-lysine to inactivate the
3 The abbreviations used are: DAT, dopamine transporter; CNX, calnexin;
COPII, coatomer protein II; ER, endoplasmic reticulum; ERAD, ER-associ-
ated degradation;MDCK,Madin-Darby canine kidney; PBA, sodium4-phe-
nylbutyrate; TM, transmembrane domain; ANOVA, analysis of variance.
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free biotin, the cells were lysed with 1 lysis buffer as described
elsewhere (24). A portion of the lysate was saved to determine
the total protein content, and the remainder was incubated
with streptavidin-agarose beads for 2 h at room temperature
with rotary shaking. After centrifugation, the supernatant was
removed, and an aliquot was used to quantify the non-biotiny-
lated fraction. The agarose beads recovered were washed three
times with 1 lysis buffer, and the bound proteins (biotiny-
lated) were eluted with Laemmli buffer (65 mM Tris, 10% glyc-
erol, 2.3% SDS, 100 mM DTT, 0.01% bromphenol blue) for 10
min at 75 °C. The samples were then analyzed inWestern blots.
Immunofluorescent Staining of Cultured Cells—Immunocy-
tochemistry was performed as described (31). Briefly, MDCK II
cells, COS7 cells, or primary neurons were fixed with 4% para-
formaldehyde in PBS, washed three times with 1ml of PBS, and
then blocked for 30 min with 10% serum in TNT (0.1 M Tris/
HCl (pH 7.5), 0.3 M NaCl, and 0.2% Triton X-100). The cells
were then incubated for 2 hwith the desired primary antibodies
(E-cadherin (rat, 1:200), CNX (rabbit, 1:500), GFP (mouse,
1:200), or RFP (rabbit, 1:1000)) diluted in TNT containing 1%
serum (TNT-S), after which they were washed three times with
TNT buffer and incubated for 2 h with the appropriate second-
ary antibody diluted in TNT-S (anti-mouse Alexa Fluor 488
(1:200), anti-rabbit Alexa Fluor 555 (1:200), or anti-rat or anti-
rabbit Alexa Fluor 647 (1:200)). After three washes with TNT,
the coverslips were mounted on microscope slides with
Vectashield (Vector Laboratories, Burlingame, CA), and the
cells were visualized by confocal microscopy on an inverted
microscope AXIOVERT200 (Zeiss). At least 30 images for each
condition were quantified using ImageJ software (National
Institutes of Health) (as in Ref. 33). The images were processed
with a 2.0-pixel median filter, and the threshold applied was
automatically determined by the JACoP plugin (34). Pearson’s
value of correlationwas obtainedwith JACoP by comparing the
two thresholded channels and measuring the correlation
between them. The value can range from 1 to 1, the latter
representing maximal co-localization (two identical images).
Electrophoresis and Western Blotting—Protein samples were
separated by SDS-PAGE using a 4% stacking gel and 6 or 7.5%
resolving gels. The samples were transferred to nitrocellulose
(Invitrogen) (1.2 mA/cm2 for 2 h), and the membranes were
then blocked for 4 h with 5% milk in PBS at 25 °C. The mem-
branes were probed overnight at 4 °C with the desired primary
antibody: anti-GlyT2 (rabbit, 1:1,000) (35); anti-GlyT2 (rat,
1:500) (36); anti-CNX (1:1,000; Stressgen Biotechnologies
Corp.); anti-ubiquitin (P4D1, 1:200; Santa Cruz Biotechnology,
Inc.); anti-HA (monoclonal antiserum 12CA5, 1:500; Sigma);
anti-GFP (green fluorescent protein, 1:1,000; Invitrogen); or
anti-RFP (red fluorescent protein, 1:2,000; a generous gift of
José María Requena, Centro de Biología Molecular Severo
Ochoa). After several washes, the antibodies bound were
detected with peroxidase-coupled anti-rat (1:8,000; Sigma) or
anti-rabbit IgG (1:10,000; Bethyl), which were visualized by
enhanced chemiluminescence (ECL; Amersham Biosciences).
Subsequently, the antibodies were stripped from the mem-
brane (Thermo Scientific), which was reprobedwith anti-tubu-
lin (1:3,000; Sigma), and antibody binding was detected with a
peroxidase-coupled anti-mouse IgG. The protein bands were
quantified by densitometry.
Carbohydrate Modification—COS7 cells expressing GlyT2
or the desired mutants were lysed in 1 lysis buffer (150 mM
NaCl, 50mMTris-HCl (pH 7.4), 5 mM EDTA, 1%Triton X-100,
0.1% SDS, 0.25% deoxycholate sodium, 0.4mMPMSF, and 4M
pepstatin) and digested with the chosen endoglycosidase (pep-
tide:N-glycosidase F (New England Biolabs) or endoglycosidase
HorD (RocheApplied Science)) in a small volumeof the appro-
priate buffer, according to the manufacturer’s instructions.
These cell extracts were then resolved by SDS-PAGE and ana-
lyzed in Western blots.
Immunoprecipitation Assays—Transfected COS7 cells were
washed twice with PBS and scraped off of the plates in 150 mM
NaCl, 50 mM Tris-HCl (pH 7.4), 0.4 mM PMSF, and 4 M pep-
statin, and the desired amount of protein (Bradford method,
Bio-Rad) was solubilized for 30 min at 22 °C in lysis buffer with
0.2%Nonidet P-40. After a 15-min centrifugation at 10,000 g,
an aliquot of the lysatewas retained tomeasure the total protein
content, and the remainder was precleared by adding 20 l of
50% protein A or G Sepharose (Sigma) in lysis buffer for 30min
at 4 °C with rotation. After centrifugation, the supernatants
were incubated overnight at 4 °C with 2 g of the desired pri-
mary antibody, whereas controls with no antibody were also
included. Subsequently, 20 l of protein A or G-Sepharose
beads were added to the samples, and after incubating for 1 h at
4 °C, the beads were washed twice for 5 min with 500 l of 1
lysis buffer. The bound proteins were then dissociated from the
beads by heating at 75 °C for 15 min, resolved by SDS-PAGE,
and analyzed in Western blots. Sequential immunoprecipita-
tions were performed as described elsewhere (24). Beads con-
taining anti-CNX immunoprecipitated proteins were incu-
bated with 150 l of 1% SDS in HEPES-buffered saline at 75 °C
for 30 min and centrifuged. The supernatant was then diluted
with 1.35ml of 1% CHAPS in HEPES-buffered saline (final SDS
concentration, 0.1%), transferred to a new tube, and incubated
with an anti-GlyT2 antibody (1.5 g) overnight at 4 °C. The
immunocomplexes formed were again recovered with fresh
beads, eluted, and analyzed as above.
Pulse-Chase Experiments—Cells cultured to 80–90% conflu-
ence in p60 or p100 plates were maintained in methionine-free
medium for 1 h prior to performing the pulse-chase experi-
ments (24). The cells were then pulse-labeled for 15 min with
0.25 mCi/ml [35S]methionine/cysteine (Redivue Promix,
Amersham Biosciences) and chased for varying periods in
DMEM  10% fetal calf serum (FCS) containing 1 mM cyclo-
heximide to quickly stop the elongation of nascent polypeptide
chains. Labeling was quenched by the addition of ice-cold PBS
containing 20 mM freshly prepared N-ethylmaleimide to pre-
vent the oxidation of free sulfhydryl groups. The proteins were
immunoprecipitated from the cell lysates with a GlyT2 anti-
body (35) or sequentially with anti-CNX (Stressgen) and anti-
GlyT2 antibodies as described above. The samples were
resolved by SDS-PAGE, fixed, and treated with Amplify fluo-
rography reagent (AmershamBiosciences). The gels were dried
and exposed for 4–12 days at 70 °C, and the protein bands
were quantified by densitometry.
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Primary Cultures of Cerebral Cortex—Primary cultures of
embryonic cortical neurons were prepared as described previ-
ously (37). Briefly, the cortex ofWistar rat fetuses was obtained
on the 18th day of gestation, and the tissue was mechanically
disaggregated in Hanks’ balanced salt solution (Invitrogen)
containing 0.25% trypsin (Invitrogen) and 4 mg/ml DNase
(Sigma). Cells were plated at a density of 500,000 cells/well in
6-well plates (Falcon), and they were incubated for 4 h in
DMEM 10% FCS, containing glucose (10 mM), sodium pyru-
vate (10 mM), glutamine (0.5 mM), gentamicin (0.05 mg/ml),
streptomycin (0.1 mg/ml), and penicillin G (6 105 mg/ml).
After 4 h, the buffer was replaced with Neurobasal/B27 culture
medium containing glutamine (0.5 mM, 50:1 by volume; Invit-
rogen), and 3 days later, cytosine arabinoside (2.5–5  103
mM) was added to inhibit further glial growth. For transfection,
neurons that had beenmaintained in vitro for 7 days were incu-
bated with 2g of total DNAmixed with 4l of Lipofectamine
2000 reagent (Invitrogen). GlyT2 glycine transport and mem-
brane expression were measured after 48 h in culture.
Densitometry and Data Analysis—The protein bands visual-
ized by ECL (Amersham Biosciences) or fluorography were
quantified in a GS-800 calibrated imaging densitometer using
the Bio-Rad Quantity One software, with film exposures in the
linear range. Non-linear regression fits of experimental trans-
port data were performed using ORIGIN software (Microcal
Software, Northampton,MA). The error bars represent the S.E.
of at least triplicate samples, and the representative experi-
ments shown were repeated no fewer than three times with
comparable results.
RESULTS
S512R Exerts a Dominant Negative Effect on the Wild-type
GlyT2—Scanning the 16 coding exons of the human GlyT2
gene (SLC6A5) in a cohort of hyperekplexia patients recently
revealed a missense mutation in exon 10 associated with dom-
inant autosomic inheritance (10). This mutation yields a pro-
tein with a serine to arginine substitution in transmembrane
domain 7 (S512R), forwhich a dominant negative role onGlyT2
trafficking was proposed. To characterize this effect, we
expressed the recombinant S512R mutant together with the
wild-type GlyT2 in eukaryotic cells, and we measured the
mutant’s effect on GlyT2 membrane expression and on gly-
cine transport (Fig. 1).We employed an optimized co-transfec-
tion protocol that makes use of low amounts of cDNA to avoid
saturating the cell’s translation machinery (see “Experimental
Procedures”). Accordingly, only specific effects were observed
that allowed us to characterize the dominant negative behavior
of the mutant.
As we reported previously (24), when expressed in heterolo-
gous cells, GlyT2 appears as a doublet of two protein bands in
Western blots; the mature transport-competent form that is
present at the plasma membrane migrated as a 100 kDa band,
and the immature hypoglycosylated transporter appeared as a
75-kDa protein band. When the S512R mutant was expressed
heterologously, no 100 kDa band was evident inWestern blots,
and the molecular weight of the sole protein band detected was
compatible with that of the 75-kDa immature form (Fig. 1A).
Thus, it was not surprising that the S512R transporter was inac-
tive. Indeed, when the mutant was co-expressed with the wild-
type GlyT2, the amount of the 100 kDa band and glycine trans-
port were both reduced to 42.1 4.5 and 51.0 5.3% (mean
S.E.) of the original values, respectively. Furthermore, the sur-
face mature wild-type transporter available for biotinylation
was reduced in a dose-dependent manner when co-expressed
with increasing amounts of S512R mutant. Thus, equal
amounts of wild-type and mutant DNA (1:1 condition) caused
the wild-type surface expression to decrease to 43.1  2.2%
(biotinylated GlyT2) and glycine transport to decrease to
37.1 2.2% of their original values (Fig. 1, B andC), whereas 2-
and 3-fold increases in the concentration of co-expressed
mutant (1:2 and 1:3 conditions) produced further reductions in
membrane expression (to 24.5  2.3 and 18.6  1.6%, respec-
tively) and in transport activity (to 21.5 1.8 and 14.8 1.7%,
respectively). By contrast, whenwild-typeGlyT2was expressed
together with increasing amounts of another inactive GlyT2
mutant (G485C) that reached the plasma membrane normally,
glycine transport was unaltered (Fig. 1, B and D). Likewise,
when increasing concentrations of S512R were co-expressed
with the non-related GLT1 (glutamate transporter 1), neither
GLT1 plasmamembrane expression nor the transport of gluta-
mate was affected (Fig. 1, B and E). These results confirm a
dominant negative role of S512R on wild-type GlyT2 and indi-
cate that the mutant acts specifically on the wild-type GlyT2.
Besides, this behavior is not a general feature of GlyT2mutants
but rather a particular property of S512R.
The ability of S512R to reduce the amount of wild-type
GlyT2 at the cell surface was also monitored in MDCK cells
through its co-localization with the plasma membrane marker
E-cadherin (Fig. 1F). For this purpose, we used constructs of
wild-type andmutant fused toN-terminal tags. The tags did not
interfere with either glycine uptake or with the plasma mem-
brane expression of the fusion proteins (see Fig. 5A).We co-ex-
pressed the wild-type and mutant GlyT2 fused to GFP or RFP,
and we analyzed the cells by immunofluorescence to detect
E-cadherin. The images show that the RFP-S512R fusion pro-
tein was clearly absent from the plasma membrane, and the
presence of themutant strongly diminished the surface expres-
sion of the wild-type GFP-GlyT2. Thus, the co-localization of
GFP-GlyT2 with E-cadherin was reduced to 50.4 2.5% when
it was co-expressed with RFP-S512R rather than with RFP-
GlyT2 (right histogram). Therefore, theGFP- or RFP-tagged (or
HA-tagged) transporter constructs reproduced the dominant
negative behavior of the mutant transporter as well as replicat-
ing the properties of the wild-type transporter.
S512R Characterization—The failure to detect a mature
S512R transporter suggests that the missense mutation pre-
vents the progression along the secretory pathway. To deter-
mine whether the removal of the serine or the introduction of
the arginine impeded post-translational processing of the
transporter, we evaluated multiple amino acid substitutions at
position 512 (Fig. 2A). Surface biotinylation of the mutants
expressed in COS7 cells led us to conclude that the lack of a
mature transporter at the cell surface was due to the introduc-
tion of the arginine. Indeed, this feature was also observed for a
similar substitution at the contiguous position 511, where the
presence of an arginine residue also impaired the production of
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the mature transporter and glycine transport. By contrast,
other substitutions were permissive for processing and activity,
and although the transport activity of alanine and cysteine
mutants was about half that of the wild type, only the serine to
threonine mutation restored (and even improved) glycine
transport (Fig. 2A, right histogram). Glycine transport by Ser-
512mutants did not fully correlate with membrane expression,
implying that the substitutions affect the activity of surface
transporters in addition to their processing. This was predict-
able because Ser-512 is close to the Na1-coordinating residue,
Asn-511. Notably, a serine substitution has been found at this
adjacent site associated with hyperekplexia (N511S), yielding a
mutant that is almost completely inactive but that reaches the
cell surface (10).
We next studied the glycosylation state of the S512R mutant
to determine its location in the secretory pathway (Fig. 2B).
Treating cell lysates expressing wild-type GlyT2 with peptide:
N-glycosidase F completely removed theN-linked glycans from
both the 75- and 100-kDa forms, yielding a 60 kDa band. This
corresponded to the non-glycosylated protein core because its
apparent size coincided with that of the N1234D mutant that
lacks the fourN-glycosylationmotifs (24). Themature 100 kDa
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FIGURE 1. S512Rmutant has a dominant negative effect on GLYT2 trafficking. A, COS7 cells expressing GlyT2, S512R, or both (1:1 cDNA ratio, by weight)
were assayed in Western blots (left) and for glycine transport (right). The 100-kDa mature transporter in the Western blot (arrow) was densitometered and is
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band was resistant to endoglycosidase H, indicating that it con-
tained complex oligosaccharides, which would be consistent
with a protein that has exited the ER, undergone oligosaccha-
ride processing in the Golgi, and reached the cell surface. By
contrast, the immature 75 kDa band was sensitive to Endo-H,
indicating that it contained high mannose oligosaccharides
borne by proteins in the ER. The glycosidase sensitivity of the
S512Rmutant paralleled that of thewild-type immature 75 kDa
band, indicating that the mutant transporter resides in the ER.
The persistence of the S512R mutant in the ER suggests that
this transporter is misfolded. Proteins that are folded incor-
rectly and are retained in the ER may be sorted for ER-associ-
ated degradation (ERAD) (38). Because most ERAD substrates
are ubiquitinated by polychain addition prior to their degrada-
tion, we assessed the ubiquitination state of the wild-type and
mutant transporters. As such, the HA-GlyT2 or HA-mutant
transporter (see Fig. 5A) was immunoprecipitated from trans-
fected COS7 cells with an anti-HA antibody, and the proteins
recovered were analyzed inWestern blots probed with an anti-
ubiquitin (P4D1) antibody (Fig. 2C). Because ubiquitination
regulates the endocytosis, recycling, and turnover of themature
GlyT2 (31, 37), it was not surprising that the 100 kDa band
detected in the wild-type lysate was strongly ubiquitinated.
Nevertheless, the ratio of ubiquitin to HA immunoreactivity
was higher for the S512Rmutant than the wild type (1.0 0.23
versus 1.6 0.19%), suggesting that S512R is modified by ubiq-
uitination to a higher extent than thewild-typeGlyT2. This was
confirmed by immunoprecipitating the transporter with a KF2
multiubiquitin antibody (data not shown). In agreement with
this, the S512R mutant was more prone to degradation. Cells
expressing the wild-type or mutant transporter were treated
with cycloheximide to block further protein synthesis, and a
time course of transporter expressionwasmonitored by immu-
noblotting at serial time intervals (Fig. 2D). Although mature
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wild-type GlyT2 had a half-life above 20 h (24), the amount of
the mutant transporter was reduced by 50% within 2 h (49.7
6.3%). Interestingly, the disappearance of the immature 75-kDa
wild-type GlyT2 was faster than that of S512R, suggesting that
maturation of GlyT2 was quicker than degradation of S512R.
Thus, these results suggest that the S512R mutant is more
prone to ERAD than wild-type GlyT2.
The Association of S512R with Calnexin Is Enhanced—The
ER is a site where quality control of the glycoproteins synthe-
sized takes place. Elements in the ER, such as molecular chap-
erones and lectins, recognize folding intermediates and
undergo rounds of binding and release to facilitate or rescue
folding, suppress aggregation, or mediate the retention and
subsequent degradation of aberrant proteins. We recently
showed that CNX plays an important role in the quality control
of GlyT2 in the ER. The 75-kDa GlyT2 precursor transiently
binds to CNX, which facilitates GlyT2 processing (24), and
thus, the retention of the mutant in the ERmay possibly reflect
a more robust or long lasting association with CNX. Therefore,
we studied the association of this chaperone to the wild-type or
mutant transporter by confocal microscopy. In MDCK cells
expressing either GFP-GlyT2 or RFP-S512R and immuno-
stained for CNX, S512R co-localized more strongly with CNX
than the wild-type GlyT2, as evident through the almost 2-fold
increase in the Pearson value for the mutant (0.24 0.006 ver-
sus 0.13  0.003; Fig. 3A). Although these data suggest
enhanced association to CNX of the mutant, the presence of
mature and immature transporter forms in the wild type may
make it difficult to compare with the co-localized fluorescence
of the single-form mutant. Therefore, we assessed the amount
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of untagged wild-type or mutant transporter recovered when
Nonidet P-40 lysates of cells expressing these constructs were
immunoprecipitated with an antibody against CNX. The
amount of S512R co-precipitated from cells expressing this
mutant with the CNX-specific antibody was 6-fold (6.4 0.07)
higher than theGlyT2 recovered fromcells expressing thewild-
type (Fig. 3B). This difference in steady-state binding might
reflect a stronger or longer lasting association of the mutant
transporter with CNX. To assess this possibility, sequential
immunoprecipitation of [35S]methionine/cysteine pulse-
chased cells expressing thewild-type ormutant transporterwas
performed, whereby cell lysates were first immunoprecipitated
with a CNX-specific antibody after a 15-min labeling pulse and
the desired chase, and the immunocomplexes recovered were
then immunoprecipitated with a GlyT2 antibody (Fig. 3C). In
this way, a fraction of the protein bound to CNX in steady state
could be isolated, and when the immunoprecipitation was
performed after longer chases, we could estimate the half-
life of the CNX-transporter complexes. Accordingly, the wild-
type GlyT2 75-kDa precursor transiently associated with CNX
in a complex with a half-life of around 60 min, at which point
the 100-kDa mature transporter was formed (24). By contrast,
the complex in which the mutant associated with CNX was
much more stable (right graph), and this persistent association
with CNX might lead to its retention in the ER.
Alterations in the Association of S512R with Sec24D—Cargo
transport from the ER to the Golgi is mediated by COPII vesi-
cles that bud off from the ER exit sites. ER export signals are
thought to be recognized by the Sec24 subunit of the Sec24-
Sec23 protein complex that forms the inner layer of the COPII
coat. A binding site for Sec24 resides in the C terminus of sev-
eral SLC6 transporters, which mostly depend on the Sec24D
isoform for ER export (26, 32, 39). One possibility that could
explain the slow dissociation of S512R from CNX is a distorted
interaction of themutantwith theCOPII, such that the delivery
from the chaperone is impaired. To test this possibility, we
expressed Myc-Sec24D protein in COS7 cells together with
either the wild-type GlyT2 or S512R transporter, immunopre-
cipitated the cell lysates with a GlyT2-specific antibody, and
probed the immunocomplexes inWestern blots to detectMyc-
Sec24D. The amount of Myc-Sec24D co-immunoprecipitated
with the 75-kDawild-type GlyT2was 4-fold (4.3 0.12) higher
than that recovered with the mutant (Fig. 4A). This interaction
was independent of theMyc tag because aMyc-tagged negative
control did not interact with the transporters (Fig. 4B). This
suggests that the binding of the mutant to Sec24D is somehow
altered, and as a consequence, S512R is not exported from the
ER.
S512RFormsOligomerswithWild-typeGlyT2—Uponreleaseof
the lumenal ER chaperones, most exportable proteins oli-
gomerize, which helps to relieve ER entrapment. However, by
forming heteromers with the S512R mutant, it is possible that
the wild type could be retained in the ER. To test this hypothe-
sis, we immunoprecipitated lysates of cells expressing differ-
ently tagged wild-type and mutant transporters (HA or RFP
N-terminal fusions of the transporters that do not interfere
with expression or function; Fig. 5A), and using a specific anti-
body against one tag, we monitored the co-precipitation of the
other transporter by Western blot. Due to the small size of the
HA epitope (less than 1 kDa), the HA-tagged transporters were
virtually indistinguishable from the untagged counterparts, so
that HA-GlyT2 showed the two bands of about 100 and 75 kDa,
and HA-S512R showed the 75 kDa band. By contrast, the pRFP
vector used contained a tandem dimer variant of DsRed (27)
that increased the size of the bands by 75 kDa, such that
RFP-S512R appeared as a 150 kDa band, and RFP-GlyT2
appeared as a doublet of 175 and 150 kDa. Some additional
bands were also observed due to the tendency of the untagged
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or tagged 75-kDa form to generate higher molecular weight
forms, clearly recognizable in the GlyT2 Western blots. Also,
some small proteolytic products were observed, such as two
bands slightly above 100 and 75 kDa. When the anti-HA anti-
body was used to immunoprecipitate the transporter from cells
expressing HA-GlyT2 and RFP-S512R, alone and in combina-
tion (a condition that gave cleanWestern blotswhenprobed for
HA, RFP, or GlyT2; Fig. 5B, left), both tagged proteins were
present in the HA immunoprecipitate, indicating that the wild
type and mutant interact. This interaction was also detected
when we exchanged the tags and co-expressed HA-S512R with
RFP-GlyT2 and probed Western blots of the immunocom-
plexes obtained with anti-HA for RFP-GlyT2 (Fig. 5B, right).
Notably, the 150 kDa RFP-tagged band was that primarily
recovered from these cells, suggesting that the wild-type-mu-
tant interactionmainly involves the 75-kDa ER wild-type form.
A similar result was obtained when HA was used to immuno-
precipitate complexes from cells co-expressing HA-GlyT2 and
RFP-GlyT2, indicating that also for thewild-type, the immature
forms do interact. The amount of RFP-GlyT2 co-immunopre-
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cipitated with HA-S512R was 2-fold (2.0  0.45) higher than
that co-immunoprecipitated with HA-GlyT2, suggesting a
stronger association of the wild type with the mutant than with
other wild-type molecules (Fig. 5C, right histogram).
CNX Overexpression Rescues Wild-type GlyT2 from the
Dominant Negative Effect of S512R—Because the S512R
mutant showed enhanced association to CNX (Fig. 3) and it
also interacts with wild-type GlyT2 (Fig. 5), we asked whether
overexpressing CNX might affect the interaction between the
wild-type and mutant transporter. Recombinant CNX was
overexpressed in cells co-expressing HA-GlyT2 and RFP-
S512R, and the amount of the RFP-mutant transporter co-pre-
cipitatedwithHA-GlyT2 from the cell lysates was quantified by
densitometry inWestern blots probed for RFP-S512R (Fig. 6A).
CNX overexpression preferentially favored the accumulation
of wild-type GlyT2 in the cells and significantly reduced the
mutant/wild-type ratio in the immunocomplexes (bottom left
histogram). In addition, total transporter expression was
increased by the chaperone, consistent with our previous
results showing that CNX facilitated GlyT2 biogenesis (24).
However, the weaker contribution of RFP-S512R to the com-
plexes was not due to a general increase in transporter expres-
sion because enhancing transporter expression by doubling the
amount of transporter cDNA used in the transfection did not
alter mutant and wild-type co-immunoprecipitation. This was
due to the fact that overexpressed CNX increased wild-type
transporter expression to a greater extent than mutant expres-
sion, which probably reflects the chaperone’s ability to discrim-
inate between different conformational states of GlyT2 (24).
The overexpression of CNX in COS7 cells co-expressing GFP-
GlyT2 and RFP-S512R also provoked a significant decrease in
the co-localization of wild-type and mutant immunofluores-
cence, reflected in the drop in the Pearson value to 59.09 
0.12% of its value at endogenous CNX levels (0.44 0.09 versus
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0.26  0.03; Fig. 6B). Remarkably, when the wild-type and
mutant transporters were co-expressed, the stronger co-local-
ization of S512R/CNX relative to wild type/CNX that was
observed when the transporters were expressed alone with
CNX (Fig. 3) was barely or not evident (see “Discussion”).
To determinewhether CNXoverexpression could rescue the
function of wild-type GlyT2 from the dominant negative effect
of S512R, untagged transporters were expressed alone or
together at a 1:1 ratio (whichwe expect tomimic heterozygosis)
in the presence of increasing concentrations of CNX, assessing
membrane expression and glycine transport in these cells (Fig.
7). The amount of CNX was monitored by densitometry and
normalized to tubulin immunoreactivity (bottom histograms).
The capacity of the S512R mutant to form a functional trans-
porter with mature glycosylation could not be rescued by CNX
despite a 3-fold increase in the amount of 75-kDa S512R that
was detected. By contrast, an increase in the concentration of
CNX produced partial rescue of the function and membrane
expression of wild-type GlyT2 when it was co-transfected with
S512R (right panels). Interestingly, the recovery of transporter
activity was slightly higher than the enhancement ofmembrane
expression, suggesting either more efficient folding of the
membrane transporter in the presence of the chaperone (24) or
a CNX-induced stimulation of transport activity of unknown
nature.
Rescue ofWild-typeGlyT2 from theDominantNegative Effect
of the S512R Mutant by Chemical Chaperones—The previous
results suggest that treatments increasing the expression or
accelerating the processing and membrane translocation of
GlyT2 could rescue the dominant negative effect produced by
S512R. Folding mutants of some membrane proteins, such as
ATP-binding cassette transporters, can be corrected with
ligands/substrates (40, 41). Although the pharmacology of
GlyT2 is very scarce, we incubated transfected COS7 cells dur-
ing the protein processing of this transporter (48 h post-trans-
fection) with several glycine analogues known to inhibit GlyT2
transport to some extent (42). Only glycine produced some res-
cue (27.3 5.1% of transport and 10.1 2.6% of mature trans-
porter; Fig. 8A), although a minor effect was also detected with
glycine methyl ester. Conversely, neither the specific GlyT2
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inhibitor ALX1393 nor sarcosine, a GlyT1-specific substrate,
could provoke significant rescue (data not shown). We next
assessed general chemical chaperones, drugs that can aid the
folding ofmembrane proteins and accelerate their trafficking to
the membrane. These compounds belong to three main classes
of osmolytes (43): carbohydrates (glycerol, sorbitol, and inosi-
tol); amino acids and derivatives (glycine, taurine, alanine, and
proline); andmethylamines (betaine and trimethylamineN-ox-
ide). Hence, we tested several representatives of each class,
together with substances that influence cell proteostasis and
other more generally accepted chemical chaperones: sodium
4-phenylbutyrate (PBA) (44) and the autophagy inducer treha-
lose (45). Like CNX, no compound produced any effect on
S512R expressed alone; however, the transport activity of wild-
type GlyT2 when expressed alone or together with S512R was
significantly stimulated (increases of 40–60%) by dimethyl
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sulfoxide (DMSO), PBA, glycerol, taurine, and betaine. Thus,
the wild-type GlyT2 was rescued from the dominant negative
effect of S512R (Fig. 8B). Of these compounds, DMSOand glyc-
erol produced some toxicity on the cells (not shown), whereas
taurine and betaine were effective at very high concentrations
(100 mM). By contrast, the maximal effect of PBA was observed
at 1 mM, and it produced an increase in glycine transport
(40.6  9.6%, mean  S.E.) and membrane expression of the
active transporter (38.1 9.5%, mean S.E.) comparable with
CNX (Fig. 8C). In addition, no toxic effects on COS7 cells were
detected, aswould be expected for a compound approved by the
United States Food andDrugAdministration for use in humans
(46).
In light of these data, we assayed this compound in primary
cortical neurons, which displayed robust surface co-localiza-
tion of two differentially tagged wild-type transporters (GFP-
GlyT2 and RFP-GlyT2). However, GFP-GlyT2 and RFP-S512
co-expression in these cells reproduced the dominant negative
effect observed in non-neural cells, with strong intracellular
staining of both transporters and reduced surface expression of
the wild-type GlyT2 (Fig. 9A). Indeed, when the dominant neg-
ative effect detected in neurons was quantified, it was compa-
rablewith that observed inCOS7 cells (Fig. 9B). It is noteworthy
that the size of the immature and mature GlyT2 was barely
distinguishable in Western blots of neurons, probably due to
neuron-specific patterns of glycosylation.4 Nevertheless, the
expression was strong enough to measure robust transport
activity in the presence of the GlyT1 inhibitor NFPS (about 5
and 1.3 nmol of glycine/mg of protein/7 min in GlyT2 and
mock-transfected neurons, respectively). The expression of the
wild-type andmutant transporters at a 1:1 ratio reduced GlyT2
membrane expression to 34.1  5.3 and glycine transport to
42.5 4.1% (mean S.E.). Moreover, a further increase in the
concentration of the co-expressed mutant provoked an addi-
tional decrease in transporter expression and function.
Remarkably, PBA (1 mM) promoted significant rescue of this
effect and restored both membrane expression (92.6  8.6%)
and glycine transport (86.1 8.4%) of the active GlyT2 co-ex-
pressedwith themutant in these primary neurons. Thus, for the
first time, our results show the possibility of overcoming the
dominant negative effect of the S512R mutant in a neuronal
preparation.
DISCUSSION
In this report, we have verified and characterized the domi-
nant negative effect of the S512R mutant of GlyT2, whose co-
expression with the wild-type transporter provokes a consider-
able reduction in glycine transport and prevents it from
reaching the plasma membrane, both in COS7 cells and in pri-
mary cortical neurons.
S512R is a folding-defective mutant that does not produce a
mature transporter; rather, the immature transporter is
retained in the ER. Its apparent molecular weight and glycosi-
dase sensitivity indicates its processing is arrested after receiv-
ing the first preassembled glycans, transferred by the oligosac-
charyltransferase to the Asn-X-Ser/Thr consensus sites from
the lipid dolichol-pyrophosphate donor in the ER membrane.
The glycans are then rapidly trimmed in a co-translational
manner by the sequential action of glucosidases I and II to gen-
eratemonoglucosylated side chains that support binding to lec-
tin chaperones like CNX (47). For this reason, S512R is a pre-
ferred substrate for CNX, and its association with the
chaperone is stronger than that of the wild-type transporter, as
witnessed by co-immunoprecipitation and fluorescence co-im-
munolocalization. This association provokes the ER retention
of the mutant transporter. Retention of misfolded proteins in
the ER leads to their polychain ubiquitination, a signal for deg-
radation by the 26 S proteasome through ERAD. Our results
indicate that CNX-retained S512R is targeted for ERAD
because it is more intensely ubiquitinated than the wild-type
GlyT2 and it has a much shorter half-life. The fact that CNX
overexpression cannot rescue the mutant indicates that chap-
erone binding precedes degradation and not maturation, as
occurs in the wild type.
Misfolding of S512R seems to be due to the introduction of
the large positive charged arginine rather than the removal of
the serine. Two additional hyperekplexia-associated missense
mutations have been identified in the same TM7 region, both
predicting clashes or disturbances of crucial residues involved
in Na1 and Cl coordination (N511S and S515I, rat position
numbering) (10, 12). Hence, substitutions in this important
region alter the protein’s function, although only severe struc-
tural alterations may provoke its misfolding. This suggests that
Ser-512, which is located at the membrane-exposed surface of
the transporter, may expose motifs (hydrophobic patches or
unpaired cysteines) involved in chaperone binding when
replaced by arginine. In the recently modeledDrosophilaDAT,
the serine homologous to Ser-512 is situated in a groove
between TM5 and TM7, where a cholesterol molecule is bound
to the transporter. Therefore, Ser-512, although not directly
involved in the binding of cholesterol, is shielded by the bound
cholesterol molecule, and it may influence the binding site. A
modulatory role in maintaining an outward-open state of the
transporter has been proposed for the cholesterol-binding site
(19). As in DAT, the GlyT2 transport is modulated by choles-
terol, and the transporter displays optimal transport activity
when included in lipid rafts (31). The modulation of transport
by cholesterol suggests a connection between the cholesterol
binding site and the substrate binding site. New data from the
DAT crystal suggested that the bound cholesterol molecule
modulates the movement of TM1a that occurs during the
transport cycle. TM1a is connected to internal loop 1, which in
turn is hydrogen-bonded to the C-terminal latch of the trans-
porter. In several SLC6members, this region contains the bind-
ing site for the cargo receptor of the COPII complex Sec24 that
permits ER export (26, 39), and C-terminal deletion mutants of
GlyT2 are retained in the ER (32). We have demonstrated that
the interaction of wild-type GlyT2with Sec24D is altered in the
S512R mutant. Although this alteration has to be confirmed
with endogenous Sec24D in neural preparations, we hypothe-
size that the S512Rmutation causes structural distortion of the
cholesterol modulatory region that is transmitted to the C-ter-
minal latch and that somehow influences the interaction with
4 E. Arribas-González, J. de Juan-Sanz, C. Aragón, and B. López-Corcuera,
unpublished results.
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COPII to provoke its retention in the ER. It is tempting to spec-
ulate that cholesterol binding to themutantmight be impaired,
although this could not be proven in our hands due to the
effects of altering cholesterol concentrations on the proteosta-
sis of the cells (data not shown) (50).
In this study, we have also shown that wild-type GlyT2 forms
oligomers with the S512R mutant and that this interaction is
more stable than its binding to other wild-type molecules. This
interactionmainly takes place in the ER, such that ER retention
of the wild-type/mutant oligomers prevents the progression of
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GlyT2 through the secretory pathway and explains the domi-
nant negative behavior of themutant. CNXoverexpression res-
cues this effect, suggesting that the wild-type and mutant iso-
forms compete for binding to the chaperone, which may
facilitate the selective transport of the wild-type folded trans-
porter to the plasma membrane (24). The fact that the associa-
tion of S512R with the wild-type GlyT2 is diminished in the
presence of overexpressed CNX, despite its more persistent
binding to CNX and its enhanced association with the wild-
type isoform, sustains the selective role of the chaperone.GlyT2
oligomerization was previously shown after transporter cross-
linking (49). Our data confirm that oligomer formation is
required for ER export, as demonstrated for other SLC6 trans-
porters (26). Therefore, the immature GlyT2 forms appear to
bind to CNX prior to the formation of oligomers, and they are
subsequently exported from the ER to continue transporter
maturation.
Chemical chaperones are non-selective small molecules that
stabilize mutant proteins and accelerate their membrane traf-
ficking, reminiscent of the chaperoning function of intracellu-
lar molecular chaperones (43). Due to this activity, chemical
chaperones may potentially have therapeutic value to improve
ER stress-related pathologies (41). Most chemical chaperones
are osmotically active, such that they equilibrate cellular
osmotic pressure during ER crowding.Here, the effect of chem-
ical chaperones in the rescue of GlyT2was analyzed in cultured
cells and transfected cortical neurons. According to CNX
action, no effect of any of these compounds was seen on S512R
expressed alone. However, the influence of these molecules on
the dominant negative effect of the mutant allows us to specu-
late on the conditions that might favor correct GlyT2 folding.
The calcium concentration seems not to be critical for GlyT2
folding because no significant effect was observed in the pres-
ence of compounds that reduce (thapsigargin) or increase (dil-
tiazem) ER calcium levels. Conversely, substantial rescue was
detected with the antioxidant molecule DMSO, in agreement
with the high number of cysteines present in GlyT2. The
osmotically active compounds glycerol, taurine, and betaine
promote significant rescue, suggesting that some ER crowding
takes place. Moreover, although we found no protein kinase-
like endoplasmic reticulum kinase phosphorylation, we did
detect some increase in BiP expression (2.3  0.4-fold), sug-
gesting some enhancement of the unfolded protein response
(50) when the mutant was expressed or co-expressed with the
wild type. However, no effect was observed for activators of the
proteasome (IU1) (44) or autophagy (trehalose) (45) or inhibi-
tors of bulk aggregation (guanabenz) (44). Still, our data did
indicate that PBA produces significant rescue in mild condi-
tions that produce no toxic effects, both in COS7 cells and in
cultured neurons. PBA increases GlyT2 transport activity and
plasma membrane expression by fulfilling chaperone-like
activity, as proven for other misfolded pathogenic proteins (44,
51). PBA is an interesting compound because not only is it a
chemical chaperone approved by the Food and Drug Adminis-
tration for use in humans, but it can also pass across the blood-
brain barrier, and it has been implicated as a protective agent in
neurodegenerative diseases involving ER stress (52). Therefore,
PBA may potentially rescue the dominant negative effect of
GlyT2 mutants inherited in heterozygosis, positively affecting
glycinergic neural transmission by acceleratingmembrane traf-
ficking of GlyT2. Our results support the possibility that selec-
tive pharmacoperones (17) that may enter cells and may bind
specifically to misfolded mutant GlyT2, correct its folding, and
allow correct routing have potential therapeutic effects in
hyperekplexia.However, furtherwork along these linesmust be
carried out to confirm this hypothesis.
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